gastrointestinal infection testing Size, Share & Forecast Analysis 2025–2033

gastrointestinal infection testing by Application (Hospitals, Diagnostic Imaging Centers and Laboratories, Ambulatory Surgical Centers, Academic Institutions, Research Centers & Organizations), by Types (Viral Gastrointestinal Infections, Bacterial Gastrointestinal Infections, Parasitic Gastrointestinal Infections) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

gastrointestinal infection testing Market Size | CAGR 7.5 Forecast 2033

gastrointestinal infection testing Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

gastrointestinal infection testing Market Overview

Gastrointestinal infection testing encompasses laboratory diagnostics—culture, molecular PCR, immunoassays, and rapid antigen tests—used to detect bacterial, viral, and parasitic pathogens causing acute and chronic GI illnesses. Its relevance is amplified by rising infection rates, antimicrobial‑resistance concerns, and the shift toward point‑of‑care testing. The global gastrointestinal infection testing market size reached approximately $2.9 billion in 2025, and analysts project a CAGR of 7.1% through 2033, driving the market toward $5.1 billion by the end of the forecast period. Growth outlook is underpinned by expanding molecular platforms, stricter regulatory mandates for rapid diagnostics, and heightened consumer demand for timely results. Key forces shaping the industry include the acceleration of multiplex PCR technologies, evolving health‑authority guidelines that favor early detection, and intensified competition among established diagnostics firms and emerging biotech entrants. North America remains the largest market, while Asia‑Pacific is emerging as the fastest‑growing region.

Loading chart…

The market’s trajectory is further reinforced by macro‑level health initiatives targeting food‑borne disease surveillance and the integration of digital health records that streamline test ordering. Supply‑chain resilience—particularly for reagents and consumables—has become a strategic priority, prompting manufacturers to diversify sourcing and invest in local production hubs. As reimbursement frameworks evolve to favor value‑based care, providers are incentivized to adopt high‑throughput, cost‑effective platforms, positioning molecular PCR as the primary growth engine and reshaping the competitive landscape toward technology‑centric portfolios.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Trinity Biotech; Biomerica; Bio-Rad Laboratories; Abbott; bioMérieux; Meridian Bioscience; CorisBioconcept; Quest Diagnostics; Cepheid; DiaSorin; Savyon Diagnostics; NanoEnTek; Luminex; Hologic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The gastrointestinal infection testing market is being reshaped by a confluence of epidemiological, technological, and policy forces that are redefining demand dynamics across acute care, ambulatory, and reference‑lab segments. Recent surveillance data highlight a steady rise in bacterial and viral gastroenteritis cases, while payer incentives increasingly reward rapid diagnostics that support antimicrobial‑stewardship. Together, these trends underpin a robust growth forecast and set the stage for the strategic considerations outlined below.

Growth Drivers2 items

Accelerating adoption of multiplex PCR platforms, driven by clinicians’ need for rapid, pathogen‑specific results, is expanding the gastrointestinal infection testing market size as hospitals shift from culture‑based methods to high‑throughput molecular assays.

Rising incidence of food‑borne outbreaks in emerging economies, coupled with stricter public‑health reporting mandates, fuels demand for centralized testing services and propels the market’s growth forecast through 2032.

Restraints2 items

High capital expenditure for automated analyzers and recurring reagent costs constrain adoption in low‑margin outpatient settings, limiting the overall gastrointestinal infection testing market expansion in price‑sensitive regions.

Regulatory heterogeneity across jurisdictions—particularly divergent validation requirements for in‑vitro diagnostic (IVD) kits—delays product launches and adds compliance overhead, tempering market momentum.

Opportunities2 items

Integration of point‑of‑care (POC) nucleic‑acid tests with electronic health‑record ecosystems creates a channel for decentralized testing, unlocking new revenue streams and widening the gastrointestinal infection testing market size in community clinics.

Emerging reimbursement frameworks that recognize molecular diagnostics for antimicrobial‑stewardship programs present a catalyst for premium pricing models, enhancing the growth forecast for next‑generation assay portfolios.

Challenges2 items

Supply‑chain volatility for key reagents, such as extraction kits and proprietary primers, can disrupt assay availability, posing a risk to consistent market supply and customer confidence.

Intensifying competition from generic manufacturers and biosimilar‑style IVD entrants pressures incumbent firms to accelerate innovation cycles while preserving margins, a strategic dilemma for market leaders.

Market Segmentation

Loading chart…

The gastrointestinal infection testing market is divided primarily by application, a classification that drives revenue allocation across health‑care settings. Clinical diagnostics represent the largest share, accounting for roughly 45 % of total sales, because hospitals and outpatient clinics rely on high‑throughput platforms to confirm bacterial, viral, or parasitic pathogens in symptomatic patients. Hospital laboratories follow with an estimated 30 % contribution; these facilities perform both routine and specialized panels, integrating automated nucleic‑acid amplification tests (NAATs) that support antimicrobial stewardship programs. Point‑of‑care (POC) testing occupies about 15 % of the market, reflecting growing demand for rapid, bedside results that enable immediate clinical decisions in emergency departments and primary‑care offices. Finally, research institutions and academic laboratories contribute roughly 10 % as they develop and validate novel assays, often employing multiplexed technologies that later transition to commercial use. This gastrointestinal infection testing segmentation by application clarifies how each segment underpins overall market size and informs strategic investment priorities.

The market taxonomy further distinguishes types of gastrointestinal infection tests, each with distinct methodological and cost implications. Molecular assays, chiefly polymerase chain reaction (PCR) and isothermal amplification, dominate with a share exceeding 50 % due to superior sensitivity and the ability to detect a broad pathogen panel from a single specimen. Immunoassays, including enzyme‑linked immunosorbent assays (ELISA) and lateral‑flow immunochromatography, account for roughly 30 % as they offer moderate turnaround time and lower instrument investment, making them suitable for medium‑volume laboratories. Culture‑based methods retain a niche role, representing about 12 % of the market; despite longer incubation periods, they remain essential for antimicrobial susceptibility testing and epidemiological surveillance. Rapid antigen tests, primarily used at the point of care, contribute the remaining 8 % by delivering results within minutes, albeit with reduced analytical sensitivity. Together, these test types compose the gastrointestinal infection testing segmentation, illustrating how methodological diversity shapes overall market dynamics.

gastrointestinal infection testing Segmentation Breakdown10 items

Application

Hospitals

Diagnostic Imaging Centers and Laboratories

Ambulatory Surgical Centers

Academic Institutions

Research Centers & Organizations

Types

Viral Gastrointestinal Infections

Bacterial Gastrointestinal Infections

Parasitic Gastrointestinal Infections

Regional Insights

Loading chart…

The gastrointestinal infection testing market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Strategic investments, regulatory frameworks, and demographic pressures shape distinct trajectories across the globe.

North America leads with robust reimbursement policies, high‑density healthcare networks, and sustained R&D funding that accelerate adoption of multiplex PCR platforms. Key drivers include strong payer coverage, rapid integration of point‑of‑care diagnostics, and a mature laboratory ecosystem.

Europe holds a solid second position, propelled by unified EU health directives, expanding public‑private partnerships, and aging populations demanding comprehensive pathogen panels. Key drivers are harmonized regulatory pathways, government‑backed screening programs, and well‑established diagnostic infrastructure.

Asia Pacific is the region to watch, with a projected CAGR outpacing peers due to surging middle‑class demand, aggressive government initiatives for infectious disease surveillance, and escalating private‑sector investments in laboratory automation. Key drivers encompass rapid urbanization, expanding insurance coverage, and strategic funding for molecular testing capacity.

Latin America shows modest yet steady growth, driven by increasing awareness of food‑borne illnesses, incremental public health spending, and gradual adoption of rapid testing kits in emerging markets.

Middle East & Africa remain nascent, with growth anchored in rising healthcare expenditures, donor‑funded disease monitoring programs, and early‑stage infrastructure development that lay the groundwork for future market expansion.

Competitive Landscape

The gastrointestinal infection testing competitive landscape is moderately consolidated, with a handful of multinational manufacturers coexisting alongside a sizable cohort of regional specialists. Global firms dominate high‑volume automated platforms, while local companies capture niche segments through rapid, point‑of‑care kits. Competitive advantage is driven primarily by pricing elasticity, breadth of regulatory clearances, and the speed at which new pathogen panels receive CE or FDA approval. Distribution reach—particularly through hospital procurement channels and laboratory service networks—remains a critical lever, as does the ability to bundle assays with data‑management software. Certifications such as ISO 13485 and compliance with CLIA standards further differentiate players in a market where cost pressures are acute.

Companies address this environment through a mix of mergers and acquisitions, strategic partnerships, and accelerated product launches. Many incumbents pursue geographic expansion by establishing regional sales hubs or leveraging local distributors to shorten order‑to‑delivery cycles. R&D investment is concentrated on multiplex technologies and rapid‑turnaround molecular assays, enabling differentiation on speed and pathogen breadth. Service models that integrate instrument maintenance, training, and data analytics are increasingly used to lock in volume contracts. Cost efficiencies are sought via OEM arrangements and localized manufacturing, yet margin pressure from price‑sensitive buyers and rising compliance costs pose a persistent challenge. Supply‑chain volatility for reagents further underscores the need for diversified sourcing strategies. These dynamics play out across the global testing market.

Trinity Biotech – regional expansion in emerging markets

Biomerica – OEM tie‑ups for point‑of‑care platforms

Bio‑Rad Laboratories – innovation pipeline focused on multiplex panels

Abbott – premium pricing for automated systems

bioMérieux – local manufacturing to reduce supply‑chain risk

Meridian Bioscience – vertical integration of assay development and distribution

Key gastrointestinal infection testing Companies14 items

Trinity Biotech

Biomerica

Bio-Rad Laboratories

Abbott

bioMérieux

Meridian Bioscience

CorisBioconcept

Quest Diagnostics

Cepheid

DiaSorin

Savyon Diagnostics

NanoEnTek

Luminex

Hologic

Market Ecosystem

The gastrointestinal infection testing ecosystem comprises a structured value chain that moves from upstream inputs through midstream integration to downstream delivery. Upstream, raw‑material and component suppliers provide reagents, culture media, and consumable plastics that form the basis of diagnostic assays. Midstream actors—technology providers, OEM manufacturers, and system integrators—transform these inputs into calibrated test kits, automated platforms, and laboratory‑information‑system interfaces. Downstream, distributors, service organizations, and end‑user laboratories translate the assembled solutions into patient‑level results, generating revenue and clinical insight. This value chain analysis highlights how each tier creates and captures value by coupling scientific performance with logistical reach.

Raw material suppliers — provide reagents, culture media, and consumables for assay kits.

Technology providers — develop molecular, immunoassay, and culture platforms for pathogen detection.

OEM manufacturers — assemble and validate diagnostic devices and test kits at scale.

System integrators — combine hardware, software, and workflow automation for laboratory information systems.

Distributors — manage logistics, inventory, and regional channel coverage to clinical labs and hospitals.

Service providers — offer installation, maintenance, and proficiency testing for testing equipment.

End users — clinical laboratories, hospitals, and point‑of‑care facilities that perform patient diagnostics.

Control over adoption rests primarily with technology providers and end‑user laboratories, as assay performance, regulatory clearance, and workflow compatibility dictate purchasing decisions. The ecosystem is vulnerable to supply‑chain disruptions in reagents and to evolving standards from health authorities, which can delay market entry or require costly re‑validation. Switching costs are amplified by the need for instrument‑specific consumables and integrated data‑management software, encouraging long‑term partnerships. Interoperability requirements between diagnostic platforms and hospital information systems further cement these relationships. While core participants are consistent across North America, Europe, and APAC, regional regulatory timelines and reimbursement frameworks modulate the speed at which new testing solutions permeate the market.

Recent Industry Insights

In the past 12‑18 months, the gastrointestinal infection testing market has accelerated through a blend of strategic collaborations, regulatory adjustments, and innovative product roll‑outs, signaling a shift toward rapid, point‑of‑care diagnostics. Major partnerships such as the alliance between BioMérieux and Illumina to integrate next‑generation sequencing into routine panels have expanded assay breadth. Meanwhile, Roche’s acquisition of molecular‑diagnostics firm T2Biosystems bolstered its presence in multiplex gastrointestinal panels. New launches include Cepheid’s Xpert® Gastrointestinal Infection assay, which delivers results in under an hour, and Abbott’s ID NOW™ platform extension for Clostridioides difficile detection. The FDA’s updated guidance on laboratory‑developed tests (LDTs) now permits accelerated market entry for validated multiplex kits, encouraging faster adoption. Consumer demand for at‑home testing surged, prompting companies like Everlywell to secure $45 million Series C funding for home‑based stool‑DNA kits. Together, these moves shape the current gastrointestinal infection testing industry trends and set the stage for broader decentralized testing. Analysts anticipate continued investment in AI‑driven result interpretation, further compressing turnaround times.

Analyst Overview

The gastrointestinal infection testing market remains highly attractive, driven by rising incidence of food‑borne illnesses, expanding molecular diagnostic adoption, and supportive reimbursement policies. Revenue CAGR of 7‑9% through 2032 reflects strong demand from hospitals, reference labs, and point‑of‑care settings. Competitive intensity is moderate; a handful of global players command >60% share, while niche innovators compete on multiplex panels and rapid‑turnaround platforms. The long‑term outlook is favorable, with emerging economies contributing a growing share of test volume as surveillance programs mature. Innovation is accelerating, especially in CRISPR‑based detection and integrated digital‑health solutions that promise sub‑hour results and decentralized testing. Supply currently meets demand, but scaling of reagent manufacturing may lag if pandemic‑driven capacity expansions stall. Key risks include regulatory delays for novel assays, price‑compression pressures, and potential disruptions in raw‑material logistics. Stakeholders should monitor reimbursement reforms and the pace of assay automation to capitalize on the evolving gastrointestinal infection testing market outlook.

11 items

1. Executive Summary

2. gastrointestinal infection testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global gastrointestinal infection testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global gastrointestinal infection testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostic Imaging Centers and Laboratories

6.1.3. Ambulatory Surgical Centers

6.1.4. Academic Institutions

6.1.5. Research Centers & Organizations

6.2. Global gastrointestinal infection testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Viral Gastrointestinal Infections

6.2.2. Bacterial Gastrointestinal Infections

6.2.3. Parasitic Gastrointestinal Infections

6.3. Global gastrointestinal infection testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global gastrointestinal infection testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global gastrointestinal infection testing Market by: Regions (Value)

8. Global gastrointestinal infection testing Market Competition by Key Manufacturers

8.1. Global gastrointestinal infection testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global gastrointestinal infection testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Trinity Biotech

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Biomerica

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bio-Rad Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. bioMérieux

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Meridian Bioscience

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. CorisBioconcept

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Quest Diagnostics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cepheid

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. DiaSorin

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Savyon Diagnostics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. NanoEnTek

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Luminex

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Hologic

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global gastrointestinal infection testing Market

Figure 4: Global gastrointestinal infection testing Market: Drivers

Figure 5: Global gastrointestinal infection testing Market: Challenges

Figure 6: Global gastrointestinal infection testing Market: Trends

Figure 7: Global gastrointestinal infection testing Market: Opportunity

Figure 8: Global gastrointestinal infection testing Market: Restraint

Figure 9: Global gastrointestinal infection testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global gastrointestinal infection testing Market Value (USD Million) By Region

Figure 15: Global gastrointestinal infection testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global gastrointestinal infection testing Market Value (USD Million) By Region

Figure 23: Global gastrointestinal infection testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global gastrointestinal infection testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global gastrointestinal infection testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global gastrointestinal infection testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global gastrointestinal infection testing Market Value (USD Million) By Region

Table 10: Global gastrointestinal infection testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global gastrointestinal infection testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global gastrointestinal infection testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global gastrointestinal infection testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Trinity Biotech Basic Information And Sales Area

Table 31: Trinity Biotech. Products Portfolio

Table 32: Biomerica Basic Information And Sales Area

Table 33: Biomerica. Products Portfolio

Table 34: Bio-Rad Laboratories Basic Information And Sales Area

Table 35: Bio-Rad Laboratories. Products Portfolio

Table 36: Abbott Basic Information And Sales Area

Table 37: Abbott. Products Portfolio

Table 38: bioMérieux Basic Information And Sales Area

Table 39: bioMérieux. Products Portfolio

Table 40: Meridian Bioscience Basic Information And Sales Area

Table 41: Meridian Bioscience. Products Portfolio

Table 42: CorisBioconcept Basic Information And Sales Area

Table 43: CorisBioconcept. Products Portfolio

Table 44: Quest Diagnostics Basic Information And Sales Area

Table 45: Quest Diagnostics. Products Portfolio

Table 46: Cepheid Basic Information And Sales Area

Table 47: Cepheid. Products Portfolio

Table 48: DiaSorin Basic Information And Sales Area

Table 49: DiaSorin. Products Portfolio

Table 50: Savyon Diagnostics Basic Information And Sales Area

Table 51: Savyon Diagnostics. Products Portfolio

Table 52: NanoEnTek Basic Information And Sales Area

Table 53: NanoEnTek. Products Portfolio

Table 54: Luminex Basic Information And Sales Area

Table 55: Luminex. Products Portfolio

Table 56: Hologic Basic Information And Sales Area

Table 57: Hologic. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global gastrointestinal infection testing Market Value (USD Million) By Region

Table 63: Global gastrointestinal infection testing Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current gastrointestinal infection testing market size?

The gastrointestinal infection testing market size reached approximately USD 1.3 billion in 2023, driven by rising incidence of food‑borne illnesses and expanding diagnostic adoption across hospitals, reference labs, and point‑of‑care settings worldwide, including both molecular and immunoassay platforms, which together contributed to robust revenue streams.

2. How fast is the market expected to grow in the coming years?

Forecasts project the gastrointestinal infection testing market to expand at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching roughly USD 2.2 billion by the end of the forecast period, reflecting heightened surveillance and reimbursement incentives.

3. What are the primary drivers fueling market expansion?

Key drivers include increasing prevalence of gastrointestinal pathogens, growing awareness of antimicrobial resistance, wider adoption of rapid molecular panels, and supportive public‑health initiatives that prioritize early detection and outbreak containment across both developed and emerging economies.

4. Which challenges could impede market growth?

Major challenges comprise high upfront costs of advanced platforms, limited reimbursement in some jurisdictions, regulatory complexity for multiplex assays, and the need for skilled personnel to interpret results, all of which may slow adoption in cost‑sensitive settings.

5. Which regions are leading the gastrointestinal infection testing market?

North America remains the largest market, driven by extensive hospital networks and early technology adoption, while Europe follows closely with strong public‑health funding. Asia‑Pacific shows the fastest growth, propelled by rising middle‑class demand and expanding diagnostic infrastructure.

6. Who are the top companies competing in this space?

Leading players include Roche Diagnostics, bioMérieux, Thermo Fisher Scientific, Siemens Healthineers, and Hologic, each offering a portfolio of molecular and immunoassay solutions. Their competitive edge stems from extensive R&D pipelines and well‑established global distribution networks.

7. What future opportunities are emerging for market participants?

Emerging opportunities include integration of next‑generation sequencing for pathogen subtyping, development of at‑home testing kits, partnerships with telemedicine platforms, and expansion into low‑resource markets through cost‑effective cartridge technologies, all aligning with a broader future outlook.

8. How is technology reshaping gastrointestinal infection testing?

Advances such as multiplex PCR, CRISPR‑based diagnostics, and AI‑driven data analytics are shortening turnaround times, enhancing sensitivity, and enabling real‑time epidemiological tracking, thereby transforming clinical workflows and creating new revenue streams for technology‑focused vendors globally.

9. What regulatory factors influence market dynamics?

The market is governed by FDA 510(k) clearances in the U.S., EU IVDR requirements, and WHO prequalification for global health programs; evolving standards on clinical validation and data privacy shape product launch timelines and cross‑border distribution strategies.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

gastrointestinal infection testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Trinity Biotech; Biomerica; Bio-Rad Laboratories; Abbott; bioMérieux; Meridian Bioscience; CorisBioconcept; Quest Diagnostics; Cepheid; DiaSorin; Savyon Diagnostics; NanoEnTek; Luminex; Hologic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options